| abstract |
Compositions and methods for the treatment of haematopoietic and lymphoid malignancies including CD99+ acute myelogenous leukemias (AML), myelodysplastic syndromes (MDS) and T-cell neoplasms. Disclosed compositions comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates myeloid or lymphoid malignant cell-surface expressed CD99, ( c) promotes the capping/clustering/aggregation myeloid or lymphoid malignant cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ myeloid or lymphoid malignant cells. Disclosed methods comprise administering an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and a chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5-azacytidine, and decitabine. |